SMS Pharmaceuticals' record is clean on its face: an unqualified audit opinion for FY2025-26 with one Key Audit Matter, a stable auditor since 2017, and no regulatory pattern beyond two minor paid fines. The material issues sit outside the audited numbers: a ₹45.63 crore disputed tax demand left unprovided, an IBC petition and unresolved arbitrations, obligations pledged for an associate's debt, and a revenue base concentrated in one unnamed customer.
Key findings
- A ₹45.63 crore disputed tax demand sits unprovided, alongside an IBC petition and unresolved arbitrations
Major- An Income Tax Assessment Order dated 22.03.2025 raised a ₹45.63 crore demand for AY 2023-24, over half of annual PAT, after the assessing officer rejected the books and used GSTR-1 turnover of ₹740.29 crore against the company's declared ₹522.05 crore. The company has appealed and made no provision, believing the demand will not be sustained. Separately, an operational creditor's Section 9 IBC petition alleging a ₹3.02 crore default remained pending as of the FY2025-26 Annual Report. - VKT Pharma stake pledged for NCDs; Exim Bank undertaking given
Major- In FY2023-24, SMS Pharmaceuticals pledged all its shares in associate VKT Pharma, investment value ₹45 crore, towards VKT Pharma's NCDs to Avendus Finance. On 16 October 2025, it gave Exim Bank an undertaking for VKT Pharma's ₹150 crore term loan refinancing those NCDs. Carrying amounts of pledged assets were ₹493.97 crore in FY2019-20 and ₹1,167.78 crore in FY2025-26. - Related-party support concentrates in promoter-linked VKT Pharma and Haleos Labs
Major- Shareholders approved pledging the 36.55% VKT Pharma stake for its ₹130 crore NCDs, with the company charging 1% commission. VKT Pharma contributed ₹14 crore to FY26 PAT of ₹102 crore. FY2025-26 AOC-2 shows sales to VKT Pharma of ₹54.65 crore and purchases from Haleos Labs of ₹17.02 crore; the AGM notice seeks material RPT approval with VKT Pharma up to ₹175 crore. - Promoter family consolidates control through warrants, board seats, and remuneration above SEBI limits
Major- Promoter holding rose to 68.07%, with pledges at 17.99%, down from 35.59% a year earlier. All 90,00,000 warrants issued at ₹127 each were converted by FY2025-26, bringing ₹85.73 crore. Mr. Ramesh Babu Potluri's FY2025-26 remuneration was 6.46 crore, a 167:1 ratio to median employee, and his proposed re-appointment seeks ₹40,00,000 per month basic salary. - Revenue is concentrated in export channels; receivables concentration swung sharply
Major- International markets generated 85% of total revenues in FY2025-26. Receivables from customers individually representing more than 5% of total trade receivables rose from ₹2,275.77 lakhs (March 31, 2022) to ₹5,168.18 lakhs (March 31, 2023) to ₹13,786.87 lakhs (March 31, 2024), then fell to ₹9,206.34 lakhs (March 31, 2025) and ₹6,859.17 lakhs (March 31, 2026). - Two new subsidiaries were created and funded, while the Spanish JV remains dormant
Minor- SMS Peptides Private Limited, incorporated 01.11.2024, reported nil turnover and received ₹6.99 crore in equity funding. SMS Colab Private Limited, incorporated 23.12.2025, reported nil turnover. The Spanish JV CHEMO SMS ENTERPRISES SL had no financial operations during FY2025-26. - Two minor SEBI procedural fines, both paid and described as inadvertent
Minor- BSE and NSE imposed ₹2,000 per day for a Nomination and Remuneration Committee composition lapse from 12 August 2024 to 7 November 2024, with fines paid on 5 December 2024 and 27 March 2025. A ₹10,000 plus GST penalty each from BSE and NSE was levied in FY2021-22 for late dividend intimation. No instances of non-compliance were reported in FY2023-24 and FY2022-23. - Clean audit opinion with one KAM, clean CARO responses, and clean internal-financial-controls opinion
Clean- Suryanarayana & Suresh issued an unqualified opinion on the FY2025-26 standalone financial statements, dated May 22, 2026, with one Key Audit Matter on revenue recognition. CARO for FY2025-26 reports no fraud, no wilful default, no undisputed statutory dues in arrears for more than six months, no cash losses, and no auditor resignation. The audit trail feature operated throughout FY2025-26 with no tampering. - The same statutory auditor, Suryanarayana & Suresh, has served since 2017 with routine reappointments through 2027
Clean- First appointed at the 29th AGM on 27 September 2017, the firm was re-appointed for a second five-year term at the 34th AGM in 2022, with 99.9976% votes in favour. No resignation of statutory auditors occurred during FY2025-26. The firm has signed every annual report from FY2022-23 through FY2025-26.
What to watch
- IBC petition outcome. The Section 9 petition by Sai Sreyas Pharmaceutical remained pending as of the FY2025-26 Annual Report.
- Tax demand appeal. The appeal and grievance petition on the ₹45.63 crore AY 2023-24 demand were pending as of the FY2025-26 Annual Report.
- 38th AGM on 29 September 2026. Shareholders vote on the ₹175 crore material RPT approval with VKT Pharma, the ₹50 crore loan/guarantee for SMS Peptides, and the CMD's re-appointment for five years from 1 October 2026.
- Land and DSIR arbitrations. The Writ Petition on the cancelled land allotment and the DIAC arbitration on DSIR assistance were both pending as of the FY2025-26 Annual Report.
- Capex completion. The ₹280 crore program is stated for completion by end of FY27.
Bottom line: This is an audited, profitable, and growing company with a clean audit record and a stable auditor. The risk character is concentration, of revenue in one unnamed customer, of support in one associate, and of control in one family, layered with litigation that is disclosed but not provided for. Read the tax demand, the VKT Pharma undertaking, and the customer concentration with that in mind, and watch the AGM votes and the pending legal outcomes.